Interested in Participating?

A clinical trial is now available for those whose cancer has spread to the skin and hasn’t responded to other treatments.

T

he pancreas is one of those body parts that people don’t know much about. Contrary to the heart or the lungs, which we feel every day working in our bodies, the pancreas is a silent gland that rarely gets mentioned.

The pancreas is a located in the abdomen, nestled between the stomach, the spleen, the small intestine, and the gallbladder, and it plays a crucial role in regulating your blood sugar levels. The other main function of the pancreas is to aid with digestion.

What Is Pancreatic Cancer?

As with most other types of cancer, pancreatic cancer occurs when cells in the pancreas begin to grow and divide at an abnormal and uncontrolled rate, forming one or several growths called tumors. However, normal cells should only grow and divide when the body needs to replace them because others have died out.

The reasons why pancreatic cancer occurs are not fully understood; it is estimated that 5 to 10% of pancreatic cancer cases can be attributed to genetic or hereditary factors, however, the rest of the cases seem to occur at random.

There are a few factors that may increase the risk of developing pancreatic cancer, including obesity, diabetes, smoking, eating processed meats, and being over the age of 60. However, a direct relationship between pancreatic cancer and these factors has yet to be established.

Pancreatic cancer is diagnosed through a combination of clinical history, imaging tests to look for any tumors or masses in or around the pancreas, lab tests, and a biopsy of any masses that were found.

Unfortunately, pancreatic cancer doesn’t produce many symptoms until it has reached a very advanced stage so it is very hard to diagnose it early. This is one of the reasons why this is one of the most aggressive types of cancer. It is estimated that 23% of individuals survive one year after the diagnosis, and only 8% are living five years post-diagnosis.

Match to Pancreatic Cancer Clinical Trials

  • Access to cutting-edge treatments
  • Latest clinical trials
  • Find trials in your area

Pancreatic Cancer Clinical Trials

Contrary to popular belief, clinical trials are not always carried out to evaluate new drugs or medications. Some cancer clinical trials have been designed to improve the way doctors diagnose pancreatic cancer and to look for ways to diagnose the disease early in order to improve the patient’s prognosis.

When you decide to enroll in a clinical trial, the first thing the research staff will ask you to do is to sign an informed consent form. An informed consent form is a document that explains all the benefits and risks associated with participating in a research study, and your signature will let the research team and regulatory agencies know that you have been informed and have voluntarily agreed to participate.

Signing an informed consent form doesn’t mean that you are not free to withdraw from the study at any point in time. Clinical research is always voluntary, and if you decide to stop participating in a clinical trial you are free to do so at any time, without facing any medical or legal consequences.

All clinical trials are different, so while some clinical trials only evaluate the participants a few times per week or per month, other studies (especially cancer clinical trials) are inpatient clinical trials, which mean that the participant will be admitted to the hospital for the duration of the study.

ClinicalTrials.gov: Recruiting Studies | Pancreatic Cancer | Last update posted in the last 300 days Studies found on ClinicalTrials.gov by a search of: Recruiting Studies | Pancreatic Cancer | Last update posted in the last 300 days

  • Training Endoscopists to Perform On-site Rapid Cytological Evaluation for EUS-FNA of Solid Pancreatic Lesions
    on August 12, 2020 at 4:00 pm

    Condition:   Pancreatic CancerIntervention:   Sponsor:   Changhai HospitalRecruiting

  • Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
    on August 4, 2020 at 4:00 pm

    Condition:   Metastatic Pancreatic CancerInterventions:   Drug: Camrelizumab;   Drug: Nab paclitaxel;   Drug: Gemcitabine InjectionSponsor:   Fudan UniversityRecruiting

  • Hair Loss Prevention Study for Pancreatic Cancer
    on July 30, 2020 at 4:00 pm

    Condition:   AlopeciaIntervention:   Device: Paxman Scalp Cooling DeviceSponsor:   HonorHealth Research InstituteRecruiting

  • NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
    on July 24, 2020 at 4:00 pm

    Conditions:   Borderline Resectable Pancreatic Adenocarcinoma;   Locally Advanced Pancreatic Ductal Adenocarcinoma;   Resectable Pancreatic Ductal Adenocarcinoma;   Stage III Pancreatic Cancer AJCC v8Interventions:   Other: Hafnium Oxide-containing Nanoparticles NBTXR3;   Radiation: Radiation TherapySponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)Recruiting

  • Assessment of What Patients and Healthcare Providers Value
    on July 23, 2020 at 4:00 pm

    Conditions:   Gastric Adenocarcinoma;   Pancreatic Adenocarcinoma;   Pancreatic Neuroendocrine CarcinomaIntervention:   Other: Survey AdministrationSponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)Recruiting

  • Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.
    on July 22, 2020 at 4:00 pm

    Condition:   Advanced Pancreatic CancerIntervention:   Drug: Irinotecan Liposome Injection combined with 5-FU/LVSponsor:   CSPC Ouyi Pharmaceutical Co., Ltd.Recruiting

  • Nutrition in Gastrointestinal Tumors
    on July 17, 2020 at 4:00 pm

    Conditions:   Pancreatic Cancer;   Oesophageal Cancer;   Colon Cancer;   Liver Cancer;   Rectal Cancer;   Bile Duct Cancer;   GIST, Malignant;   Neuroendocrine Tumors;   Small Intestine Cancer;   Gastric CancerIntervention:   Other: No intervention - observational study onlySponsor:   University Medicine GreifswaldRecruiting

  • CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
    on June 30, 2020 at 4:00 pm

    Conditions:   Hypoglycemia, Reactive;   Hypoglycaemia Night;   Hypoglycemia Non-Diabetic;   Hypoglycemia Unawareness;   Insulinoma;   Insulinoma; Malignant, Pancreas;   Insulin Hypoglycemia;   Insulin Resistance;   Spontaneous Hypoglycemia;   Neuro Endocrine TumoursIntervention:   Device: use of continuous glucose monitoringSponsor:   Barts & The London NHS TrustRecruiting

  • Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
    on June 30, 2020 at 4:00 pm

    Condition:   Pancreatic CancerIntervention:   Radiation: PLDRSponsor:   Fox Chase Cancer CenterRecruiting

  • Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study
    on June 29, 2020 at 4:00 pm

    Conditions:   Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8;   Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage 0 Gastric Cancer AJCC v8;   Clinical Stage I Esophageal Adenocarcinoma AJCC v8;   Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage I Gastric Cancer AJCC v8;   Clinical Stage II Esophageal Adenocarcinoma AJCC v8;   Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage II Gastric Cancer AJCC v8;   Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIA Gastric Cancer AJCC v8;   Clinical Stage IIB Gastric Cancer AJCC v8;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage IV Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage 0 Gastric Cancer AJCC v8;   Pathologic Stage I Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage I Gastric Cancer AJCC v8;   Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IA Gastric Cancer AJCC v8;   Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IB Gastric Cancer AJCC v8;   Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage II Gastric Cancer AJCC v8;   Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIA Gastric Cancer AJCC v8;   Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIB Gastric Cancer AJCC v8;   Pathologic Stage III Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8;   Stage 0 Colorectal Cancer AJCC v8;   Stage 0 Pancreatic Cancer AJCC v8;   Stage I Colorectal Cancer AJCC v8;   Stage I Pancreatic Cancer AJCC v8;   Stage IA Pancreatic Cancer AJCC v8;   Stage IB Pancreatic Cancer AJCC v8;   Stage II Colorectal Cancer AJCC v8;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Colorectal Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Colorectal Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage IIC Colorectal Cancer AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8Interventions:   Other: Patient Monitoring System;   Other: Questionnaire Administration;   Other: ConsultationSponsors:   Thomas Jefferson University;   National Cancer Institute (NCI)Recruiting

  • Patient Reported Outcomes Measures to Predict Pancreatic Surgery Outcomes
    on June 16, 2020 at 4:00 pm

    Conditions:   Pancreatic Cancer;   Patient Reported Outcome Measures;   Quality of Life;   Pancreatectomy;   Nutritional Status;   Recovery of FunctionIntervention:   Sponsor:   Massimo FalconiRecruiting

  • Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors
    on June 12, 2020 at 4:00 pm

    Conditions:   TNBC - Triple-Negative Breast Cancer;   Head and Neck Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Anal Canal;   Uveal Melanoma;   Glioblastoma;   Colorectal Cancer;   Chordoma;   Squamous Cell Carcinoma of the Lung;   KRAS G12D;   KRAS G13D;   EGFR Amplification;   Epithelial Ovarian Cancer;   Hepatocellular Carcinoma;   Anaplastic Thyroid Cancer;   Pancreas CancerInterventions:   Drug: BCA101;   Drug: PembrolizumabSponsor:   Bicara TherapeuticsRecruiting

Interested in Participating?

A clinical trial is now available for those whose cancer has spread to the skin and hasn’t responded to other treatments.

Are There Any Risks of Participating in a Clinical Trial?

When a clinical trial is ready to recruit volunteers, it means that the research team has spent a long time (usually years) investigating the potential medication in a lab. During that time, the treatment was tested in animals for safety and toxicity, and it met all the requirements for human subject testing mandated by internal and third-party regulatory entities.

Going through all these regulations and phases ensure that the clinical trial posses the minimal amount of risk possible for all participants. However, as it is the case of any medication (and especially experimental ones) there is always a risk for unexpected side effects, allergies, etc. so research staff is always on call in case anything happens to a participant.

Where Can I Find a Pancreatic Cancer Clinical Trial?

Hospitals and universities are always conducting research studies and clinical trials, so if you are interested in learning more about becoming a research volunteer you can call your local hospital or university. Additionally, if you or a loved one is a pancreatic cancer patient, your oncologist might be the right person to ask about clinical trial.

Match to Pancreatic Cancer Clinical Trials

  • Access to cutting-edge treatments
  • Latest clinical trials
  • Find trials in your area